A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC

医学 二线疗法 内科学 血管内皮生长因子 抗体疗法 双特异性抗体 抗体 肿瘤科 免疫疗法 癌症研究 癌症 免疫学 化疗 血管内皮生长因子受体 单克隆抗体
作者
Lei Wang,Yongzhong Luo,Shengxiang Ren,Zhihong Zhang,Anwen Xiong,Chunxia Su,Jin Zhou,Xinmin Yu,Yanping Hu,Xiaodong Zhang,Xiaorong Dong,Shuyan Meng,Fengying Wu,Xiaoming Hou,Yuanrong Dai,Weifeng Song,Baiyong Li,Zhongmin Maxwell Wang,Xia Yu,Caicun Zhou
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:19 (3): 465-475 被引量:60
标识
DOI:10.1016/j.jtho.2023.10.014
摘要

PURPOSE This study aimed to evaluate the safety and efficacy of ivonescimab (a bispecific antibody against programmed death-1 [PD-1] and vascular endothelial growth factor [VEGF]) as first- or second-line monotherapy in advanced immunotherapy naïve non-small-cell lung cancer (NSCLC) patients. METHODS Eligible patients received intravenous ivonescimab 10mg/kg every 3 weeks (Q3W), 20 mg/kg every 2 weeks (Q2W), 20 mg/kg Q3W or 30mg/kg Q3W. The primary endpoints were safety and objective response rate (ORR) per RECIST v1.1. RESULTS At data cutoff (October 5, 2022), 108 patients were enrolled and received ivonescimab. Programmed death ligand-1 (PD-L1) tumor proportion score (TPS) was ≥1% in 74 (68.5%) patients, including 35 (32.4%) with TPS ≥50%. The median follow-up was 10.4 months (range 8.4 to 10.9 months). For all patients, ORR and disease control rate (DCR) were 39.8% and 86.1%, respectively. ORR by TPS was 14.7%, 51.4% and 57.1% in patients with TPS <1%, ≥1%, and ≥50%, respectively. In the 67 PD-L1 positive patients receiving first-line ivonescimab, the ORR was 33.3%, 52.6%, 60.0%, and 75.0% at the doses of 10mg/kg Q3W, 20 mg/kg Q2W, 20 mg/kg Q3W and 30mg/kg Q3W, respectively. Grade ≥3 treatment-related adverse events (TRAEs) were observed in 24 (22.2%) patients. TRAEs leading to treatment discontinuation occurred in 1 (0.9%) patient. TRAEs leading to death occurred in 3 (2.8%) patients with squamous histology. The occurrence of grade ≥3 TRAEs and grade ≥3 bleeding events in squamous versus non-squamous histologies were 25.5% vs. 18.9% and 0.0% vs. 1.9%, respectively. CONCLUSION Ivonescimab monotherapy was well tolerated and demonstrated promising efficacy in patients with advanced or metastatic NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
YY的应助被ly普鲁卡因采纳,获得10
刚刚
cougarcmx完成签到,获得积分10
1秒前
杨柳依依完成签到,获得积分10
2秒前
jun完成签到,获得积分10
2秒前
温玉完成签到 ,获得积分10
2秒前
1111完成签到,获得积分10
3秒前
进退须臾完成签到,获得积分10
4秒前
4秒前
ljy2015发布了新的文献求助10
4秒前
丫丫完成签到 ,获得积分10
4秒前
nanfeng完成签到 ,获得积分10
4秒前
双shuang完成签到,获得积分10
4秒前
白苹果完成签到 ,获得积分10
5秒前
5秒前
一公里完成签到 ,获得积分10
6秒前
贪玩定帮完成签到,获得积分10
6秒前
shangfeng完成签到,获得积分10
6秒前
郭小逗完成签到 ,获得积分10
6秒前
共享精神的应助被wj采纳,获得10
6秒前
满目星光发布了新的文献求助10
6秒前
7秒前
zz完成签到,获得积分10
7秒前
zhuao完成签到,获得积分10
7秒前
meng完成签到,获得积分10
8秒前
帅气思烟完成签到 ,获得积分10
8秒前
若山完成签到,获得积分10
8秒前
Kristine完成签到 ,获得积分10
8秒前
jiang完成签到,获得积分10
8秒前
志123完成签到,获得积分10
8秒前
歪猴完成签到,获得积分10
9秒前
宇文天思完成签到,获得积分10
9秒前
尊敬的驳完成签到,获得积分10
9秒前
apricity199的应助被冷静幻翠采纳,获得10
9秒前
鸭子完成签到,获得积分10
9秒前
脆皮小小酥完成签到 ,获得积分10
10秒前
11秒前
zxf完成签到,获得积分10
11秒前
甜甜雪晴完成签到,获得积分10
12秒前
12秒前
滿分選手完成签到 ,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159174
求助须知:如何正确求助?哪些是违规求助? 9554642
关于积分的说明 21720253
捐赠科研通 7748830
什么是DOI,文献DOI怎么找? 3427184
关于科研通互助平台的介绍 2552091
邀请新用户注册赠送积分活动 2471464